Progyny PGNY
- Market cap
- $2.2B
- PE
- 31.5×
- 6y median 55.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.7×
- EV/EBIT
- 18.0×
- Revenue, 12 months
- $1.3B
- +6% on a year ago
- Net margin
- 6.0%
- Free cash flow yield
- 8.0%
Progyny trades at 31.5× trailing earnings, cheaper than 87% of the last ten years. Revenue was $1.3B over the last twelve months, up 6% on a year earlier with a 6% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $280.9M+37% | $269.9M+26% | $278.1M+8% | $304.1M+9% | $286.6M+2% | $298.4M+11% | $324M+17% | $332.9M+10% | $313.3M+9% | $318.4M+7% | $328.5M+1% | $350.5M+5% | |
| Cost of revenue | $218.3M+37% | $213M+25% | $215.7M+8% | $235.8M+8% | $227.4M+4% | $235M+10% | $248.2M+15% | $253.9M+8% | $240.5M+6% | $241.5M+3% | $245.4M−1% | $261.2M+3% |
| Gross profit | $62.6M+36% | $56.9M+28% | $62.4M+6% | $68.3M+13% | $59.2M−5% | $63.4M+12% | $75.8M+22% | $79M+16% | $72.8M+23% | $76.9M+21% | $83.1M+10% | $89.3M+13% |
| SG&A | $44.4M+28% | $43.1M+5% | $43.9M+1% | $47.6M+5% | $46.8M+5% | $47.6M+11% | $51.6M+18% | $54.6M+15% | $51.3M+10% | $61.7M+29% | $47.7M−8% | $49.3M−10% |
| $18.2M+62% | $13.8M+317% | $18.5M+23% | $20.7M+36% | $12.5M−32% | $15.8M+14% | $24.2M+31% | $24.4M+18% | $21.5M+73% | $15.2M−4% | $35.4M+46% | $40M+64% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $20.9M+81% | $16.3M+293% | $22.5M+38% | $25.1M+46% | $18M−14% | $17.7M+9% | $26.5M+18% | $27.1M+8% | $24M+33% | $17.9M+1% | $36.9M+39% | $41.1M+52% |
| $5M | $2.8M+281% | $5.6M | $8.6M+294% | $7.5M+50% | $7.1M+155% | $11.5M+104% | $10M+16% | $10.1M+34% | $5.4M−25% | $12.7M+10% | $13.1M+31% | |
| Net income | $15.9M+20% | $13.5M+295% | $16.9M−4% | $16.5M+10% | $10.4M−35% | $10.5M−22% | $15.1M−11% | $17.1M+4% | $13.9M+33% | $12.5M+19% | $24.2M+61% | $28.1M+64% |
| $0.16+23% | $0.13+333% | $0.17−6% | $0.17+13% | $0.11−31% | $0.12−8% | $0.17+0% | $0.19+12% | $0.15+36% | $0.14+17% | $0.29+71% | $0.34+79% | |
| 100.9M+1% | 100.7M+1% | 101.1M+1% | 97.8M−3% | 93.8M−7% | 88.9M−12% | 89.3M−12% | 89.6M−8% | 90.2M−4% | 89.5M+1% | 84.8M−5% | 82.1M−8% |
EPS, diluted: Q2 FY19: quarter's net income to common over its shares, to the cent.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Progyny's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| AVAHAveanna Healthcare | $2.9B | 10.9× | 21.8× | 1.1× | +20% | 10.6% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| NHCNational Healthcare | $3.7B | 26.5× | 21.4× | 2.4× | +7% | 9.0% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| Peer median | $2B | 24.4× | 29.2× | 1.3× | +14% | 5.3% |
Investors who own it
Investors we follow who held Progyny at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfoliotrimmed
More on Progyny
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .